Cancer is one of the leading causes of death worldwide. Conventional therapies, including
surgery, radiation, and chemotherapy have achieved increased survival rates for many types …

Following the first proof of concept of using small nucleic acids to modulate gene
expression, a long period of maturation led, at the end of the last century, to the first …

Oligonucleotide therapeutics have the potential to become a third pillar of drug development
after small molecules and protein therapeutics. However, the three approved …

Under clinical development since the early 90's and with two successfully approved drugs
(Fomivirsen and Mipomersen), oligonucleotide-based therapeutics has not yet delivered a …

It is estimated that the human genome encodes 15% of proteins that are considered to be
disease-modifying. Only 2% of these proteins possess a druggable site that the approved …

Antisense oligonucleotides (ASOs) bind sequence specifically to the target RNA and
modulate protein expression through several different mechanisms. The ASO field is an …

Antisense technology has emerged as an exciting and promising strategy of cancer therapy.
The principle of this technology is the sequence-specific binding of an antisense …

Cancer is one of the leading causes of death worldwide, and conventional cancer therapies
such as surgery, chemotherapy, and radiotherapy do not address the underlying molecular …

Highlights•Recent human clinical trial data on RNAi approaches to gene down-regulation for
genetic diseases.•Overview of current anti-microRNA drugs with specific emphasis on …

The recent acceleration in the identification and characterisation of new molecular targets for
cancer and the limited effectiveness of conventional treatment strategies has focused …